A new proteomic test could guide treatment decision in second-line therapy for patients with EGFR unselected non-small cell lung cancer?

Ítems similars

• Second-line treatment in EGFR-unselected patients: is it time to close one arm of this river’s DELTA?
  per: Morales-Espinosa, Daniela, et al.
  Publicat: (2015)
• Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer
  per: Hirsh, Vera
  Publicat: (2012)
• Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
  per: Liao, Bin-Chi, et al.
  Publicat: (2019)
• Quantitative Multiplexed Proteomics Could Assist Therapeutic Decision Making in Non-Small Cell Lung Cancer Patients with Ambiguous ALK Test Results
  per: An, Ho Jung, et al.
  Publicat: (2021)
• Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer
  per: Landi, Lorenza, et al.
  Publicat: (2015)